R-CEOP PROTOKOLÜ

Kaynaklar:

1-Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Leuk Lymphoma. 2016;57(5):1191-1193.

2-Fields PA, Townsend W, Webb A, et al. . De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, VİNKRİSTİNe, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol. 2014;32(4):282-287.

3- Alden A. Moccia, Kimberly Schaff, Ciara Freeman, et al. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Adv. 2021 Mar 9; 5(5): 1483–1489.